Drug Patent Expirations in April 2014

Drug Patent Expirations for April 2014

Tradename Applicant Generic Name Patent Number Patent Expiration
MAXALT-MLT Merck rizatriptan benzoate 5,457,895*PED Apr 1, 2014
FROVA Endo Pharms frovatriptan succinate 5,616,603 Apr 1, 2014
ABELCET Sigma Tau amphotericin b 5,616,334 Apr 1, 2014
BROVANA Sunovion arformoterol tartrate 6,589,508 Apr 3, 2014
INCRELEX Ipsen Inc mecasermin recombinant 6,207,640 Apr 7, 2014
VIRACEPT Agouron nelfinavir mesylate 5,952,343*PED Apr 7, 2014
NIZORAL A-D Mcneil Cons ketoconazole 5,456,851 Apr 7, 2014
VIRACEPT Agouron nelfinavir mesylate 5,484,926*PED Apr 7, 2014
VIRACEPT Agouron nelfinavir mesylate 6,162,812*PED Apr 7, 2014
INVEGA SUSTENNA Janssen Pharms paliperidone palmitate 5,254,556*PED Apr 15, 2014
ATELVIA Warner Chilcott Llc risedronate sodium 5,622,721 Apr 21, 2014
ALREX Bausch And Lomb loteprednol etabonate 5,540,930*PED Apr 25, 2014
LOTEMAX Bausch And Lomb loteprednol etabonate 5,540,930*PED Apr 25, 2014
ZYLET Bausch And Lomb loteprednol etabonate; tobramycin 5,540,930*PED Apr 25, 2014
ALREX Bausch And Lomb loteprednol etabonate 5,747,061*PED Apr 25, 2014
LOTEMAX Bausch And Lomb loteprednol etabonate 5,747,061*PED Apr 25, 2014
ZYLET Bausch And Lomb loteprednol etabonate; tobramycin 5,747,061*PED Apr 25, 2014
ABREVA Glaxosmithkline docosanol 4,874,794 Apr 28, 2014
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.

Contact Us with any questions.

Comments are closed.

Get email updates

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Subscribe!